EPS for Madrigal Pharmaceuticals, Inc. (MDGL) Expected At $-0.68

March 20, 2018 - By Adrian Erickson

 EPS for Madrigal Pharmaceuticals, Inc. (MDGL) Expected At $ 0.68

Analysts expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report $-0.68 EPS on April, 2.They anticipate $0.01 EPS change or 1.49 % from last quarter’s $-0.67 EPS. After having $-0.68 EPS previously, Madrigal Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.34% or $4.05 during the last trading session, reaching $125.24. About 76,324 shares traded. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has 0.00% since March 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.78 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.